Consistent with this idea, IL4 signals through JAK1 and JAK3 reduce the activity of BTK‐inhibitors in vitro, which can be restored with the JAK1/3 inhibitor tofacitinib.7 JAK inhibitors might then improve responses to ibrutinib in CLL patients. Here, JAK1 is linked to B-cell chronic lymphocytic leukemia.